Genome-Wide and Abdominal Imaging Data Characterizes Common Alleles Associated with Higher BMI and Subcutaneous Fat but Less Liver Fat and Lower Risk of Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 20-OR
Author(s):  
HANIEH YAGHOOTKAR ◽  
YINGJIE JI ◽  
ANDRIANOS M. YIORKAS ◽  
FRANCESCA FRAU ◽  
DENNIS MOOK-KANAMORI ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Lower Risk ◽  
Subcutaneous Fat ◽  
Abdominal Imaging ◽  
Liver Fat ◽  
Imaging Data ◽  
Genome Wide

scholarly journals Genome-Wide and Abdominal MRI Data Provide Evidence That a Genetically Determined Favorable Adiposity Phenotype Is Characterized by Lower Ectopic Liver Fat and Lower Risk of Type 2 Diabetes, Heart Disease, and Hypertension

Diabetes ◽  
2018 ◽  
Vol 68 (1) ◽  
pp. 207-219 ◽  
Author(s):  
Yingjie Ji ◽  
Andrianos M. Yiorkas ◽  
Francesca Frau ◽  
Dennis Mook-Kanamori ◽  
Harald Staiger ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Heart Disease ◽  
Lower Risk ◽  
Liver Fat ◽  
Genome Wide ◽  
Abdominal Mri ◽  
Ectopic Liver ◽  
Genetically Determined

scholarly journals Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial

2020 ◽  
Vol 9 (1) ◽  
pp. 259 ◽  
Author(s):  
Eugene Han ◽  
Yong-ho Lee ◽  
Byung-Wan Lee ◽  
Eun Seok Kang ◽  
Bong-Soo Cha
Keyword(s):  
Type 2 Diabetes ◽  
Fatty Liver ◽  
Visceral Fat ◽  
Controlled Trial ◽  
Subcutaneous Fat ◽  
Liver Fat ◽  
Whole Body ◽  
Alcoholic Fatty Liver ◽  
Fatty Liver Index

Despite the benefits of pioglitazone in the treatment of non-alcoholic fatty liver disease (NAFLD), many treated patients continue to experience disease progression. We aimed to investigate the additive effect of ipragliflozin on NAFLD in patients with type 2 diabetes treated with metformin and pioglitazone. In this 24-week randomized controlled trial, 44 patients with type 2 diabetes and comorbid NAFLD were either randomized to receive 50 mg/day of ipragliflozin as an add-on treatment (n = 29) or maintained on metformin and pioglitazone (n = 15). The fatty burden was assessed using the fatty liver index, NAFLD liver fat score, and controlled attenuation parameter (CAP). Changes in fat and muscle depots were measured by dual-energy x-ray absorptiometry and abdominal computed tomography scans. The enrolled patients were relatively controlled (mean baseline glycated hemoglobin of 6.6% ± 0.6%) and centrally obese (mean waist circumference of 101.6 ± 10.9 cm). At week 24, patients in the ipragliflozin add-on group exhibited reduced hepatic fat content (fatty liver index: −9.8 ± 1.9, p = 0.002; NAFLD liver fat score: −0.5 ± 0.2, p = 0.049; CAP: −8.2 ± 7.8 dB/m2, p = 0.133). Ipragliflozin add-on therapy also reduced whole-body visceral fat and the ratio of visceral to subcutaneous fat (change in whole-body visceral fat: −69.6 ± 21.5 g; change in abdominal visceral fat: −26.2 ± 3.7 cm2; abdominal visceral to subcutaneous fat ratio: −0.15 ± 0.04; all p < 0.05). In conclusion, ipragliflozin treatment significantly ameliorates liver steatosis and reduces excessive fat in euglycemic patients with type 2 diabetes and NAFLD taking metformin and pioglitazone.

The First Genome-Wide Association Study (GWAS) for Type 2 Diabetes in Youth from the Progress in Diabetes Genetics in Youth (ProDiGY) Collaboration

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1703-P ◽  
Author(s):  
SHYLAJA SRINIVASAN ◽  
JENNIFER TODD ◽  
LING CHEN ◽  
JASMIN DIVERS ◽  
SAM GIDDING ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Association Study ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide ◽  
Diabetes Genetics ◽  
Diabetes In Youth

Diabetes Remission Clinical Trial (DiRECT)—Plasma Liver Function Tests Reflect Change in Liver Fat Content in Early Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1834-P
Author(s):  
SVIATLANA V. ZHYZHNEUSKAYA ◽  
AHMAD AL-MRABEH ◽  
CARL PETERS ◽  
ALISON C. BARNES ◽  
KIEREN G. HOLLINGSWORTH ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Liver Function ◽  
Liver Function Tests ◽  
Fat Content ◽  
Diabetes Remission ◽  
Liver Fat ◽  
Early Type ◽  
Liver Fat Content

scholarly journals Genome-Wide Assessment for Resting Heart Rate and Shared Genetics With Cardiometabolic Traits and Type 2 Diabetes

2019 ◽  
Vol 74 (17) ◽  
pp. 2162-2174 ◽  
Author(s):  
Yanjun Guo ◽  
Wonil Chung ◽  
Zhaozhong Zhu ◽  
Zhilei Shan ◽  
Jun Li ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Heart Rate ◽  
Resting Heart Rate ◽  
Genome Wide ◽  
Cardiometabolic Traits
Sign in / Sign up

Export Citation Format

Share Document